Elevance Health Inc (ELV) (Q3 2026) Earnings Call Highlights: Ra
Elevance Health Inc (ELV) reported Q3 2026 adjusted EPS of $6.99, exceeding expectations. The company raised its 2026 EPS guidance to at least $29 and its earnings baseline to at least $26.75. Revenue increased to $50.4 billion, driven by higher premiums and service fees. Medical membership stood at 44.9 million, with a benefit expense ratio of 90.6%. The company expects at least 12% EPS growth in 2027, driven by margin improvements and Carelon expansion.
How this was made
The 30-second read
Why it matters
The guidance lift is a primary catalyst for the stock, likely prompting short‑term buying.
Market read
First disclosure of new EPS guidance for a large‑cap insurer; high relevance for traders.
What to watch
Higher operating expense ratio and Medicaid cost trends may temper upside.
Background
Elevance Health (ELV) reported Q3 2026 results with modest revenue growth and raised its 2026 EPS guidance.
Ticker impact
Elevance Health raised its 2026 adjusted EPS guidance to at least $29 and increased its earnings baseline, providing fresh guidance numbers.
potential upward pressure as investors price in higher earnings expectations
Guidance lift is material for a large‑cap health insurer and is the first public disclosure of the new numbers.
Market effects
Improved outlook may lift the broader health‑insurance sector as peers are re‑rated.
U.S. market may see modest gains in health‑care stocks.
Limited to U.S. insurers; minimal global spillover.
Counterpoint
Guidance raise could be premature if Medicaid cost pressures persist.
Key entities
- companyElevance Health Inc
U.S. health insurer providing the earnings data.
